The sequences of these molecules reflect clinically relevant targets previously used to correct a pathologic beta-thalassemia-associated splicing mutation in the human HBB (hemoglobin subunit beta) gene in transgenic mice (26). The gene discussed is HBB; the disease is beta thalassemia.